Inari Medical, Inc.(NARI) Stock Research - Grey Stern Research
Loading...

Inari Medical, Inc. (NARI) Stock Analysis

$46.25 (-0.58%)

NARI Financial Performance


Use the table below to view Inari Medical, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $45.95 -
52 Week Low $36.73 -
52 Week High $69.40 -
Market Cap $2.7 Billion 4/6
Gross Margin 84% 2/6
Profit Margin -21% 5/6
EBITDA margin -8% 4/6
Q2 - 2024 Revenue $145.8 Million 4/6
Q2 - 2024 Earnings -$31.3 Million 5/6
Q2 - 2024 Free Cash Flow $6.9 Million 4/6
Trailing 4 Quarters Revenue $547.5 Million 3/6
Trailing 4 Quarters Earnings -$57.1 Million 4/6
Quarterly Earnings Growth -1604% 6/6
Annual Earnings Growth -1149% 6/6
Quarterly Revenue Growth 23% 4/6
Annual Revenue Growth 17% 4/6
Cash On Hand $70.2 Million 5/6
Short Term Debt $1.9 Million 5/6
Long Term Debt $31.2 Million 4/6

Inari Medical, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Inari Medical, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/6
PS 4.89 4/6
PB 6.32 3/6
PC 38.14 3/6
Liabilities to Equity 0.59 3/6
ROA -0.08 4/6
ROE -0.13 4/6
Current Ratio 2.70 4/6
Quick Ratio 0.44 6/6
Long Term Debt to Equity 0.07 4/6
Debt to Equity 0.08 4/6
Burn Rate 2.12 2/6
Cash to Cap 0.03 4/6
CCR -0.22 6/6
EV to EBITDA -241.28 5/6
EV to Revenue 4.82 4/6

Company Details

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

CEO: Mr. William H. Hoffman

Website: https://www.inarimedical.com

Address: 9 Parker, Suite 100, Suite 100 Irvine, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Devices

Inari Medical, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Inari Medical, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Axonics, Inc. AXNX $3.5 Billion
ShockWave Medical, Inc. SWAV $12.6 Billion
Progyny, Inc. PGNY $2.2 Billion
Legend Biotech Corporation LEGN $9.2 Billion
Outset Medical, Inc. OM $27.6 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
NARI Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 145.8 Million -$31.3 Million
Q1 2024 $ 143.2 Million -$24.2 Million
Q4 2023 $ 132.1 Million -$4.7 Million
Q3 2023 $ 126.4 Million $3.2 Million
Q2 2023 $ 119.0 Million $2.1 Million
Q1 2023 $ 116.2 Million -$2.2 Million
Q4 2022 $ 107.8 Million -$5.8 Million
Q3 2022 $ 96.2 Million -$10.2 Million

View All

NARI Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $70.2 Million $672.9 Million $33.1 Million $423.8 Million
Q1 2024 $66.7 Million $661.8 Million $31.5 Million $447.2 Million
Q4 2023 $38.6 Million $674.2 Million $32.0 Million $464.9 Million
Q3 2023 $89.2 Million $548.8 Million $32.3 Million $452.1 Million
Q2 2023 $57.8 Million $525.0 Million $32.7 Million $435.6 Million
Q1 2023 $56.6 Million $506.5 Million $33.0 Million $426.7 Million
Q4 2022 $60.2 Million $504.2 Million $32.3 Million $417.0 Million
Q3 2022 $83.5 Million $487.8 Million $266.7 Million $415.1 Million

View All

NARI Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $6.9 Million -$4.6 Million $3.0 Million
Q1 2024 -$14.2 Million -$1.9 Million $28.0 Million
Q4 2023 $11.3 Million -$909,000 -$50.0 Million
Q3 2023 $14.3 Million -$1.6 Million $31.3 Million
Q2 2023 $8.5 Million -$1.2 Million $1.3 Million
Q1 2023 -$3.0 Million -$964,000 -$3.7 Million
Q4 2022 $9.5 Million -$1.8 Million -$23.3 Million
Q3 2022 -$27.2 Million -$5.1 Million $3.8 Million

View All